SMTL ID : 6n3n.1

Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 3.01 Å

Oligo State

monomer

Ligands

1 x KA4: N-{3-[(2-aminopyrimidin-5-yl)ethynyl]-2,4-difluorophenyl}-2,5-dichloro-3-(hydroxymethyl)benzene-1-sulfonamide(Non-covalent)

KA4.1: 21 residues within 4Å: Chain A: L.23, V.31, A.44, V.45, K.46, L.67, S.68, L.70, I.75, V.76, Y.78, I.104, M.106, E.107, Y.108, C.109, F.159, G.169, D.170, F.171, L.173 13 PLIP interactions: 13 interactions with chain A Hydrophobic interactions: A:A.44, A:K.46, A:K.46, A:L.67, A:L.67, A:Y.78, A:I.104, A:F.159 Hydrogen bonds: A:L.70, A:C.109, A:C.109, A:D.170, A:F.171

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Fujimoto, J. et al., Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode. Acs Med.Chem.Lett. (2019)

Release Date

2019-10-09

Peptides

eIF-2-alpha kinase GCN2,eIF-2-alpha kinase GCN2: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

eIF-2-alpha kinase GCN2,eIF-2-alpha kinase GCN2

Related Entries With Identical Sequence